Intrahepatic microRNA expression and response to peginterferon-α and ribavirin therapy in patients with chronic hepatitis C
Intrahepatic microRNA expression and response to peginterferon-α and ribavirin therapy in patients with chronic hepatitis C
批准号:
21590856
负责人:
ENOMOTO Masaru
金额:
$2.91万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2009
资助国家:
日本
项目状态:
已结题
起止时间:
2009 至 2011
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The regulated microRNAs(miRNAs) in human livers infected with hepatitis C virus(HCV) were identified by microarray analysis. MiR-422a was down-regulated, and miR-199a-5p/199a-3p and miR-221/222 up-regulated in the human liver in a fibrosis progression-dependent manner. Their expression was validated by real-time RT-PCR. Among these miRNAs, miR-222 increased in mouse livers from two fibrosis models. The expression of miR-222 was up-regulated in cultured stellate cells LX-2 and increased during the course of culture-dependent activation of mouse primary stellate cells. NF-κB inhibitor significantly suppressed the miR-222 induction that was stimulated in culture by TNF-α or TGF-α. Although over-expression or down-regulation of miR-222 failed to regulate the growth of LX-2 cells, miR-222 bound to the p27^<Kip1> 3'UTR and regulated the expression of the corresponding protein. Transient transfection with miR-222 precursors significantly up-regulated α1(I) collagen and down-regulated MMP-1 mRNA expressions. In conclusion, miR-222 may be new markers for stellate cell activation and liver fibrosis progression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
High prevalence of hepatitis C virus infection in Airin district, Osaka, Japan : A hospital-based study of 1162 patients
日本大阪爱林区丙型肝炎病毒感染率高:一项针对 1162 名患者的医院研究
DOI:
10.1111/j.1872-034x.2011.00834.x
发表时间:
2011
期刊:
Repatol Res
影响因子:
--
作者:
[Yamaguchi Y, Enomoto M, Fujii H, Tamori A, Sakaguchi H, Tanigawa T, Watanabe K, Fujiwara Y, Arakawa T, Harihara S, Monna T, Kawada N]
通讯作者:
Kawada N
Genotype 1bのC型慢性肝炎に対するPEG-IFN-α/リバビリン投与期間の個別化について:リアルタイムPCRによるresponse-guided therapyの再評価
基因型 1b 慢性丙型肝炎的 PEG-IFN-α/利巴韦林给药周期个体化:使用实时 PCR 重新评估反应引导治疗
DOI:
--
发表时间:
2009
期刊:
影响因子:
--
作者:
[中屋美香, 榎本大, 林健博, 遠山まどか, 藤井英樹, 小林佐和子, 岩井秀司, 森川浩安, 田守昭博, 坂口浩樹, 羽生大記, 塩見進, 河田則文]
通讯作者:
河田則文
Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2
对丙型肝炎病毒基因型 2 病毒载量较高的慢性肝炎患者进行反应指导治疗
DOI:
10.1111/j.1872-034x.2011.00956.x
发表时间:
2012
期刊:
Hepatol Res
影响因子:
4.2
作者:
[Yamaguchi Y, Tamori A, Tanaka Y, Iwai S, Kobayashi S, Fujii H, Morikawa H, Hagihara A, Enomoto M, Kawada N]
通讯作者:
Kawada N
Mosapride Citrate on Gastric Emptying in Interferon-Induced Gastroparesis
枸橼酸莫沙必利对干扰素引起的胃轻瘫胃排空的影响
DOI:
--
发表时间:
2012
期刊:
Dig Dis Sci
影响因子:
--
作者:
[Kawamura E, Enomoto M, Kotani K, Hagihara A, Fujii H, Kobayashi S, Iwai S, Morikawa H, Kawabe J, Tominaga K, Tamori A, Shiomi S, Kawada N]
通讯作者:
Kawada N
Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer?
曲妥珠单抗能否抑制患有慢性肝炎和乳腺癌的患者的丙型肝炎病毒?
DOI:
--
发表时间:
2011
期刊:
Am J Gastroenterol
影响因子:
9.8
作者:
[Tamori A, Kawajiri H, Takashima T, Motoyama H, Morikawa H, Enomoto M, Hirakawa K, Kawada N]
通讯作者:
Kawada N
共 19 条
Synthetic study of novel antibiotics derived from natural products using cluster effect
-
批准号:26850074
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$2.5万
-
财政年份:2014
-
负责人:ENOMOTO Masaru
-
依托单位:
Synthetic studies and SAR of the structurally complex indole diterpenes showing strong insecticidal activities
-
批准号:23780112
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$3.0万
-
财政年份:2011
-
负责人:ENOMOTO Masaru
-
依托单位:
Synthetic and SAR studies of alchivemycin, novel antibacterial and antitumor polyketide
-
批准号:21880012
-
项目类别:Grant-in-Aid for Research Activity Start-up
-
资助金额:$1.77万
-
财政年份:2009
-
负责人:ENOMOTO Masaru
-
依托单位:
海外基金